The 19th Foundation Prize will be awarded on Thursday, 4 December 2025, as part of the celebrations marking the 600th anniversary of the University of Louvain and Louvain-la-Neuve.
Exploiting CRISPR-Cas genome editing for smarter antibiotic target selection and drug design.
Exploiting the pathophysiology of the gut towards innovative treatments for gastrointestinal/metabolic diseases.
Repurposing the antidepressant sertraline to target serine/glycine synthesis addicted cancer.
Detecting Alzeimher’s pathology before memory decline using new radiopharmaceuticals.
The role of coagulates in invasive staphylococcus aureus infections.
Frontotemporal dementia caused by Progranulin mutations, treatable neurodegenerative disorders?
Pharmacological modulation of glial glutamate uptake: manipulating the cross-talks between neuroinflammation and excitotoxicity to treat neurological disorders.
Role and Therapeutic Potential of VEGF in Motor Neuron Degeneration : a Study in Transgenic Mice and Rats.
Contribution du CYP3A intestinal dans la métabolisation du midazolam chez le rat.
The Physiology, pharmacology and therapeutic potential of 5 – HT1 receptors in the gastro intestinal tract.
Biochemical activity, pharmacokinetics, and tolerability of MK-886, a leukotriene biosynthesis inhibitor, in humans.
Contribution to the development of an effective antiplatelet drug.
Détermination des shunts porto-systémiques chez l’homme par un test non invasif au d-propylène.
Pharmacologie clinique de l’induction de l’inhibition enzymatique chez des sujets hydroxylateurs déficients.
Pharmacocinétique du Fénofibrate – Contribution à l’étude de sa pharmacologie clinique.
Etude pharmacocinétique de la Daunorubicine libre et complexé à l’ADN chez le lapin et en clinique humaine.
Cardiovascular and renal effects of L-dopa : a clinical pharmacological investigation.
Psychopharmacological research versus treatment.